We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Unfazed by Setbacks, Roche Advances Its Antiamyloid Antibody Gantenerumab
Unfazed by Setbacks, Roche Advances Its Antiamyloid Antibody Gantenerumab
Gantenerumab, Roche’s prime contender of Alzheimer disease drugs in the antiamyloid antibody space, has been around the block a few times in a series of failed phase 3 studies with the suffix “RoAD.”